We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+6.62%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$869B
AUM Growth
+$32.9B
Cap. Flow
-$6.92B
Cap. Flow %
-0.8%
Top 10 Hldgs %
33.83%
Holding
3,059
New
82
Increased
1,782
Reduced
864
Closed
51

Top Buys

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$2.31B
2
AAPL icon
Apple
AAPL
+$1.58B
3
SHW icon
Sherwin-Williams
SHW
+$1.37B
4
HUBS icon
HubSpot
HUBS
+$1.32B
5
KVUE icon
Kenvue
KVUE
+$1.25B

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$4.37B
2
LRCX icon
Lam Research
LRCX
+$1.54B
3
AMAT icon
Applied Materials
AMAT
+$1.33B
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.19B
5
HAL icon
Halliburton
HAL
+$1.16B

Sector Composition

Rank Sector Weight
1 Technology 32.32%
2 Healthcare 15.15%
3 Financials 10.54%
4 Consumer Discretionary 10.48%
5 Communication Services 8.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LNZA icon
2876
LanzaTech
LNZA
$67.1M
$69K ﹤0.01%
359
WTI icon
2877
W&T Offshore
WTI
$555M
$69K ﹤0.01%
32,053
+2,644
+9% +$5.88K
PROK icon
2878
ProKidney
PROK
$304M
$68K ﹤0.01%
35,405
+16,211
+84% +$36.8K
BMTX
2879
DELISTED
BM Technologies, Inc.
BMTX
$68K ﹤0.01%
19,800
VXRT
2880
DELISTED
Vaxart
VXRT
$67K ﹤0.01%
78,500
GRTS
2881
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$67K ﹤0.01%
114,100
+51,400
+82% +$28.8K
CMPX icon
2882
Compass Therapeutics
CMPX
$427M
$66K ﹤0.01%
35,616
+7,504
+27% +$9.35K
PRPL icon
2883
Purple Innovation
PRPL
$28.4M
$66K ﹤0.01%
2,666
+266
+11% +$7.68K
KZR
2884
DELISTED
Kezar Life Sciences
KZR
$65K ﹤0.01%
8,360
TEAD
2885
Teads Holding Co
TEAD
$64.4M
$65K ﹤0.01%
13,350
MCRB icon
2886
Seres Therapeutics
MCRB
$47.4M
$64K ﹤0.01%
3,370
-10,000
-75% -$203K
TRVI icon
2887
Trevi Therapeutics
TRVI
$2.53B
$64K ﹤0.01%
19,047
PSTX
2888
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$64K ﹤0.01%
22,186
+715
+3% +$2.21K
CCLD icon
2889
CareCloud
CCLD
$104M
$63K ﹤0.01%
23,700
KYNB
2890
Kyntra Bio
KYNB
$28.7M
$63K ﹤0.01%
6,260
+2,544
+68% +$38.4K
ZURA icon
2891
Zura Bio
ZURA
$554M
$63K ﹤0.01%
+15,324
New +$57.2K
ATOS icon
2892
Atossa Therapeutics
ATOS
$23.5M
$62K ﹤0.01%
2,718
BRCC icon
2893
BRC Inc
BRCC
$215M
$62K ﹤0.01%
17,869
TCRX icon
2894
TScan Therapeutics
TCRX
$52.4M
$62K ﹤0.01%
12,301
CTV
2895
DELISTED
Innovid Corp.
CTV
$62K ﹤0.01%
34,211
SRTA
2896
Strata Critical Medical Inc
SRTA
$533M
$60K ﹤0.01%
20,288
+911
+5% +$2.9K
FARM
2897
DELISTED
Farmer Brothers
FARM
$59K ﹤0.01%
29,600
LFMD icon
2898
LifeMD
LFMD
$159M
$59K ﹤0.01%
11,117
FRGE
2899
DELISTED
Forge Global Holdings
FRGE
$58K ﹤0.01%
2,902
+656
+29% +$13.7K
PYXS icon
2900
Pyxis Oncology
PYXS
$201M
$58K ﹤0.01%
15,720

Similar funds

T. Rowe Price Associates's Q3 2024 Portfolio in Review

As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.

  • T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
  • T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
  • T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
  • T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
  • T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
  • T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
  • T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.

Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.